Table 2.
Treatment Related Toxicities and Toxicities of Interest.
| Grade ≥ 3 Adverse Events | #N = 37 (%) |
|---|---|
| Hematologic | 23 (62%) |
| Lymphopenia | 19 (51%) |
| Leucopenia | 13 (35%) |
| Neutropenia | 7 (19%) |
| Thrombocytopenia | 6 (16%) |
| Non-Hematologic | |
| Hypertension | 2 (5.4%) |
| Emesis | 1 (2.7%) |
| Elevated Lipase | 1 (2.7%) |
| Weight Loss | 1 (2.7%) |
| Transaminitis | 1 (2.7%) |
| Hyperbilirubinemia | 1 (2.7%) |
| Toxicities of Interest | |
| Weight Loss Grade 2 | 10 (27%) |
| Palmar-plantar erythrodysesthesia Grade 2 |
16 (43.2%) |
| Urine Protein ≥ 2+ on urine analysis | 12 (32.4%) |
| Pneumothorax ≤ Grade 2 | 5 (13.5%) |
| Hematuria ≥ Grade 2 | 2 (5.4%) |
#Two patients from cohort not included due to unreliable complete toxicity data.